Translational Regenerative Medicine Market is valued at USD 271.58 Million in 2020 and expected to reach USD 605.27 Million by 2027 with the CAGR of 12.13% over the forecast period.
Translational Regenerative Medicine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis. Advancement in technologies and success in CAR-T cell therapy for the treatment of cancer are some factors driving the translational regenerative medicine market.
Translational regenerative medicine very broad, new approach to medicine which uses the advances in stem cell technology. These medicines make the use of stem cell to provide clinical care is an area to fully heal damaged tissues and organs, offer solutions to critical conditions and to the damage which is beyond repair. Regenerative medicine is a branch of translational research were tissue engineering and molecular biology are involving to deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore and establish normal function. Regenerative medicine also involves the growing of tissues and organs in the laboratory and implanting it when the injury is critical, and body cannot heal itself. It is done through regenerating the cell source for an organ is derived from the patient's own tissue or cells. This approach is used in the conditions of organ transplant rejection and shortage of organs available for donation. Regenerative medicine has many other advantages over the conventional therapy including regenerative medicine therapy provide long term effects instead of treating chronic and short-term result unlike conventional therapy.
The first successful tissue engineering one in early 1980, by Howard Green and colleagues at Harvard Medical School, who described techniques to grow skin epidermis starting with a skin biopsy harvested from a patient.
Translational regenerative medicine market report is segmented based on product type, materials, application and by regional & country level. Based upon type, translational regenerative medicine market is classified into cell therapy, gene therapy, tissue engineering and small molecule & biologic. Based upon materials, translational regenerative medicine market is classified into synthetic material, biologically derived material, genetically engineered material and pharmaceuticals. Based upon application, translational regenerative medicine market is classified into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology and others.
The regions covered in this translational regenerative medicine market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of translational regenerative medicine is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Translational regenerative medicine market report covers prominent players like,
Novartis, Zimmer Biomet Holdings, Inc., MiMedx, Medtronic Plc., Athersys, Inc., Stryker Corporation, U.S. Stem Cell, Inc. Bioheart, Inc., Advanced Biohealing, Acelity Holdings, Inc., Kite Pharma, Vericel Corporation, Wright Medical, Osiris Therapeutics, and Spark Therapeutics, Organogenesis, Inc., Isto Biologics Medical Systems, Inc., Integra Lifesciences Holdings Corporation and CryoLife, Inc and among others.
Novartis Kymriah receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
News: On April 22, 2020, Novartis is the leader in pharma sector, announced that they receive FDA approval for Kymriah, intended for Regenerative Medicine Advanced Therapy designation in follicular lymphoma. Follicular lymphoma, the second most common form of non-Hodgkin’s lymphoma is an indolent lymphoma and contribute around 22% of NHL cases. Despite new treatments follicular lymphoma is remains as an incurable malignancy with a relapsing and remitting pattern. Kymriah an investigational new indication to treat patients with relapsed follicular lymphoma. Kymriah is designed to be a one-time treatment, is the first-ever FDA-approved CAR-T cell therapy.
Increasing prevalence of Chronic Diseases and Genetic Disorders across the globe over the last few decades driving the growth of regenerative medicine. For instance, rising incidence and prevalence of chronic diseases including CVD, cancer, diabetes and genetic disorders like cystic fibrosis affecting on major population across the world whereas, CVD is the leading cause of death, globally. As per the WHO, around 17.9 million people die each year from CVD, accounting for around 31% of total deaths worldwide. Similarly, the incidence and prevalence of cancer and diabetes have increased dramatically across the globe over the last decades. For instance, according to the International Diabetes Federation (IDF), about 415 million people were suffering from diabetes globally in 2015. Additionally, emergence of new technologies including, stem cell technology and untapped potential of nanotechnology fueling the growth of market. On the other flip, stringent government regulations, high cost of treatment and operational inefficiency through regenerative medicine are estimated to restrain the growth of the market. Nevertheless, regenerative medicine allows healthcare professionals to replace broken bones and develop new organs for organ transplant. This enables them to renew or replace cells in human tissues and organs which are damaged or unable to perform regular function due to injury or illness. This may create huge demand of regenerative medicine over the forecast period.
Traditional organ transplant involves the process of replacing a failing or damaged organ in the human body with a new organ. This process involves the risk of rejection as the human body does not accept organs recognized as foreign by the body’s immune system. The organ supply across the globe is insufficient, and the waiting lists for transplants are growing each day. The US government estimated that about 30 people die each day due to the unavailability of organs for transplant. To combat this concern, researchers are focusing on advancing regenerative medicine for developing organs. The increasing acceptance of regenerative medicine in organ transplants is thus considered as a major opportunity area for market.
North America is dominating the translational regenerative medicine market due to the increasing focus on stem cells therapy, growth in R&D activities and getting success in therapies in emerging economies are expected to supplement the market growth, For instance, In recent years FDA approve CART cell therapy for the myeloma cancer treatment. Additionally, increases in organ failure owing to change lifestyle creating huge demand of organ transplant in the region. For Instance, as per the US Department of Health and Human Services, approximately 120,000 people in the US were waiting for organ transplants in year of 2015. These all factors encouraging the region to dominate the market and it is expected to maintain it position over the forecast period.
Similarly, the Chinese government has approved several researches related to human embryonic stem cells that has encouraged researchers to explore the clinical potential of these cells in China. For instance, in Japan, Ministry of Health, Labor and Welfare approved regenerative medicine law in April 2013, which fuel the clinical development of regenerative and cell-based therapies. Additionally, increasing population and subsequently prevalence of chronic disease expected to bolster the market growth over the forecast period.
Report Analysis | Details |
---|---|
Historical data | 2015 - 2020 |
Forecast Period | 2021 - 2027 |
Market Size in 2020: | USD 271.58 Million |
Base year considered | 2020 |
Forecast Period CAGR %: | 12.13 % |
Market Size Expected in 2027: | USD 605.27 Million |
Tables, Charts & Figures: | 175 |
Pages | 200 |
Key Players/Companies |
Novartis, Zimmer Biomet Holdings, Inc., MiMedx, Medtronic Plc., Athersys, Inc., Stryker Corporation, U.S. Stem Cell, Inc. Bioheart, Inc., Advanced Biohealing, Acelity Holdings, Inc., Kite Pharma, Vericel Corporation, Wright Medical, Osiris Therapeutics, and Spark Therapeutics, Organogenesis, Inc., Isto Biologics Medical Systems, Inc., Integra Lifesciences Holdings Corporation and CryoLife, Inc and among others. |
Segments Covered | By Product Type, By Material, By Application |
Regional Analysis | North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa |
Global Market report covers in depth historical and forecast analysis.
Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Market report helps to identify opportunities in market place.
Global Market report covers extensive analysis of emerging trends and competitive landscape.
By Product Type
By Material
By Application
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®